trending Market Intelligence /marketintelligence/en/news-insights/trending/LYApFsH1G-opm4a_TmueqA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Approvals for Eli Lilly, Novartis; designations for Mereo, Matinas BioPharma

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Approvals for Eli Lilly, Novartis; designations for Mereo, Matinas BioPharma

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Oct. 11.

Approvals

* Eli Lilly and Co.'s Reyvow as an acute therapy for migraine with or without aura in adults.

* Novartis AG's Beovu for wet age-related macular degeneration.

* Pfenex Inc.'s PF708, a biosimilar of Eli Lilly's drug Forteo, for osteoporosis in certain patients at high risk of fracture.

* Clinuvel Pharmaceuticals Ltd.'s Scenesse to increase pain-free light exposure in adults who have a history of damage to skin resulting from erythropoietic protoporphyria.

* OraSure Technologies Inc.'s OraQuick Ebola Rapid Antigen as the first rapid diagnostic test for Ebola virus disease.

SNL ImageFDA headquarters in Silver Spring, Md.
Source: AP Photo

Fast track

* Mereo BioPharma Group PLC's navicixizumab for high-grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least three prior therapies and/or before Roche Holding AG's Avastin.

Other designations: orphan drug

* Matinas BioPharma Holdings Inc.'s MAT2203 for cryptococcosis.

* Neuren Pharmaceuticals Ltd.'s NNZ-2591 for Angelman syndrome.